Alnuctamab

DB17194InvestigationalProtein Based Therapies

Alnuctamab: Overview.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain, Tumor necrosis factor receptor superfamily member 17, and T-cell surface glycoprotein CD3
Curator reviewed
Code names: BMS-986349 · CC-93269 · EM901

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alnuctamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.